Literature DB >> 3282707

The disposition of carboplatin in the beagle dog.

R C Gaver1, A M George, G F Duncan, A D Morris, G Deeb, H C Faulkner, R H Farmen.   

Abstract

Carboplatin was administered i.v. to four groups of three male beagle dogs at doses of 3, 6, 12, and 24 mg/kg (60-580 mg/m2). Plasma samples were obtained at appropriate times and protein-free plasma ultrafiltrates (PU) were generated with Amicon Centrifree micropartition systems. Urine was collected at 24-h intervals for 96 h. PU and urine samples were analyzed for carboplatin by HPLC and for total platinum by atomic absorption spectrophotometry. Carboplatin accounted for about 90% of the free platinum in plasma. The Cmax and AUCinf values for carboplatin and for free platinum increased linearly with dose. The terminal elimination half-life and mean residence times for carboplatin and free platinum were each about 1 h. Total-body clearances for carboplatin (5.6 l/h per m2) and free platinum (5.1 l/h per m2) were constant over the dose range studied, as were the respective volumes of distribution (5.7 and 5.0 l/m2). A mean of 46% of the dose was excreted as carboplatin in 24-h urine; and by 72 h, 70% of the platinum administered was excreted in the urine. Free platinum was cleared by both renal and non-renal processes. These results show that a dose of carboplatin is rapidly excreted in the urine and that carboplatin and plasma-free platinum exhibit linear pharmacokinetics in the beagle dog.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3282707     DOI: 10.1007/bf00262769

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  5 in total

1.  Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs.

Authors:  C L Litterst; T E Gram; R L Dedrick; A F Leroy; A M Guarino
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

2.  Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; A C Jones; T J McElwain; S Raju; E Wiltshaw; I E Smith; J M Baker; M J Peckham; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  Phase I studies with carboplatin at the Royal Marsden Hospital.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; K R Harrap
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

4.  Preclinical studies identifying carboplatin as a viable cisplatin alternative.

Authors:  K R Harrap
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

Review 5.  Preclinical antitumor and toxicologic profile of carboplatin.

Authors:  W C Rose; J E Schurig
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

  5 in total
  13 in total

1.  A high-performance liquid chromatographic assay for CI-973, a new anticancer platinum diamine complex, in human plasma and urine ultrafiltrates.

Authors:  W W Bullen; L D Andress; T Chang; L R Whitfield; M L Welch; R A Newman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Platinum antitumour agents: a review of (bio)analysis.

Authors:  T J Hodes; W J Underberg; G Los; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 3.  Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.

Authors:  Anne Hulin; Jeanick Stocco; Mohamed Bouattour
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

5.  Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism.

Authors:  Mohamed Elbadawy; Yomogi Sato; Takashi Mori; Yuta Goto; Kimika Hayashi; Megumi Yamanaka; Daigo Azakami; Tsuyoshi Uchide; Ryuji Fukushima; Toshinori Yoshida; Makoto Shibutani; Mio Kobayashi; Yuta Shinohara; Amira Abugomaa; Masahiro Kaneda; Hideyuki Yamawaki; Tatsuya Usui; Kazuaki Sasaki
Journal:  Cancer Biol Ther       Date:  2021-05-26       Impact factor: 4.875

6.  Evaluation of carboplatin sustained-release delivery system in dogs with cancer.

Authors:  Colleen Tansey Baldwin; Courtney H Zwahlen; Steven Kirschner; Reid K Nakamura
Journal:  Vet Med Sci       Date:  2016-02-23

7.  Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.

Authors:  Eva-Maria Packeiser; Marion Hewicker-Trautwein; Heike Thiemeyer; Annika Mohr; Johannes Junginger; Jan Torben Schille; Hugo Murua Escobar; Ingo Nolte
Journal:  PLoS One       Date:  2020-03-13       Impact factor: 3.240

Review 8.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

9.  Comparative Pharmacokinetics and Allometric Scaling of Carboplatin in Different Avian Species.

Authors:  Gunther Antonissen; Mathias Devreese; Siegrid De Baere; Tom Hellebuyck; Isabel Van de Maele; Lieze Rouffaer; Hendrickus J J Stemkens; Patrick De Backer; An Martel; Siska Croubels
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

10.  Human Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell Lines.

Authors:  Francisco Clemente-Vicario; Carlos E Alvarez; Jennie L Rowell; Satavisha Roy; Cheryl A London; William C Kisseberth; Gwendolen Lorch
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.